Bio-Path Holdings

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)
Bellaire, US
Size (employees)
12 (est)+10%
Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, US (HQ)
210 4710 Bellaire Blvd

Bio-Path Holdings Financials and Metrics

Bio-Path Holdings Financials

Bio-Path Holdings's revenue was reported to be $13 k in FY, 2016

Net income (Q2, 2017)

(2 m)

Market capitalization (08-Dec-2017)

35 m

Cash (30-Jun-2017)

6.2 m
Bio-Path Holdings's current market capitalization is $35 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


13 k


(15.7 m)(4.5 m)(5.5 m)(8.5 m)

EBIT margin, %


Interest income

4 k22.6 k17.7 k12 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

107.6 k517 k424.5 k592.5 k564.4 k992.4 k1 m1.2 m2.3 m1 m1.5 m

General and administrative expense

786.4 k566.6 k519.9 k849 k757 k681 k970 k845 k

Operating expense total

510.2 k1.3 m1.2 m1.4 m1.1 m1.5 m1.9 m1.9 m3 m2 m2.3 m

Interest income

5.6 k6.1 k5.7 k4.3 k5.4 k4.8 k2 k2 k4 k3 k2 k
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.6 m13.9 m8.9 m9.4 m

Current Assets

3.7 m14.1 m9.6 m10.7 m


113.1 k72 k614 k

Total Assets

5.1 m15.5 m10.8 m12.2 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


16.8 m15.7 m14.6 m12.5 m11.1 m9.9 m6.5 m4.2 m11.3 m7.1 m6.2 m

Current Assets

17.2 m16 m14.9 m12.9 m12 m10.5 m7.8 m6.1 m12.4 m8.4 m7.8 m


102.8 k92.6 k82.3 k62 k51 k66 k872 k797 k

Total Assets

18.6 m17.4 m16.3 m14.2 m13.3 m11.7 m8.9 m7.1 m13.4 m10.1 m9.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.3 m)(4.5 m)(5.5 m)(6.8 m)

Depreciation and Amortization

10.3 k41.1 k43 k

Accounts Payable

(34.3 k)267.1 k375.4 k(146 k)

Cash From Operating Activities

(2.3 m)(3.8 m)(5 m)(8.1 m)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(504.9 k)(1.8 m)(2.9 m)(1.4 m)(2.5 m)(4 m)(1.9 m)(3.8 m)(5.4 m)(397 k)(2.4 m)

Depreciation and Amortization

10.3 k20.6 k30.9 k10 k21 k31 k33 k108 k

Accounts Payable

125.1 k38.6 k(11.7 k)54.3 k130.2 k(80.7 k)(37 k)(124 k)(71 k)(208 k)(257 k)

Cash From Operating Activities

(544.4 k)(1.6 m)(2.7 m)(1.4 m)(2.8 m)(4 m)(2.4 m)(4.6 m)(6.5 m)(1.8 m)(4.2 m)
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Bio-Path Holdings Market Value History

Bio-Path Holdings's Web-traffic and Trends

Bio-Path Holdings Company Life and Culture

You may also be interested in